Pfizer vaccine against covid-19 is 90% effective

Recent large-scale clinical trials have shown that the vaccine being developed by Pfizer against covid-19 is 90% effective, and may be available before the year end.

And the light at the end of the tunnel is getting bigger: the first provisional results on the effectiveness of the Pfizer / BioNTech vaccine in people show that the agent developed by the North American pharmaceutical and the German biotechnology company protects 90% of the volunteers submitted to the tests. The manufacturers’ analysis shows a much better performance than most experts expected – regulators said they would approve a vaccine as long as it was 50% effective, protecting half of those who received it.

According to the pharmaceutical company, the experimental vaccine did not cause serious side effects in the 43,000+ people involved in the phase 3 tests . “Today is a great day for science and humanity. These first results from the third phase of the clinical trial of the covid-19 vaccine provide initial evidence of our vaccine’s ability to prevent” the disease, announced the president of Pfizer, Albert Bourla, remembering that this “fundamental milestone” is reached “at a time when the world needs it most”, when new maximums of infected and deaths are being registered all over the planet.

Although it is possible that the effectiveness rate will change in the meantime, as the trial will continue, the discovery that 90% of infections have been prevented is an important step in combating the new virus. After the third week of November, the company will submit the vaccine to regulatory bodies for approval, which could mean that the first doses are administered to health professionals by the end of the year.